|
TOPIC 339 - PHASE I CONTRACT - AKRIVIS TECHNOLOGY - PO: DEEPA NARAYANAN - CO: AND
|
261201500054C
|
$299,920
|
UNKNOWN, UNKNOWN
|
AKRIVIS TECHNOLOGIES, LLC
|
|
Markers of Cognitive Decline During Treatment for Childhood ALL
|
1R21CA187226-01A1
|
$196,122
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-02
|
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
6R01CA182284-03
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
6R01CA178394-02
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-43S1
|
$199,871
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-42
|
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
6P30CA013330-43
|
$3,696,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of c-Maf in Stem cells in Leukemia
|
5F31CA162770-05
|
|
OKOYE, UJUNWA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of c-Maf in Stem cells in Leukemia
|
6F31CA162770-06
|
$43,120
|
OKOYE, UJUNWA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
5R01CA166429-03
|
$167,847
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
6R01CA166429-04
|
$216,495
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
1R01CA191077-01
|
$295,711
|
NAPPER, ANDREW
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
BCR-ABL 1 RT-QPCR TEST FOR IMPROVED MONITORING OF CML PERIOD OF PERFORMANCE: 09/
|
261201500009C
|
$1,489,494
|
BROWN, JUSTIN
|
ASURAGEN, INC.
|
|
Quantitative Superplexing: Single-tube, many-target qPCR for cancer diagnostics
|
1R43CA203403-01
|
$246,864
|
CHEN, LIANGJING
|
ASURAGEN, INC.
|
|
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
|
5R01CA160747-04
|
$324,738
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-02
|
$538,425
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-03
|
$376,095
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
1R01CA193235-01
|
$461,462
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-02
|
$399,401
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5K99CA188595-02
|
$109,361
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressive Pathways for Cancer Therapy
|
1R35CA197529-01
|
$430,779
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms of regulation by RNA in acute myeloid leukemia
|
1R35CA197697-01
|
$1,042,185
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5K99CA183914-02
|
$169,668
|
WAN, LIXIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Lig4R278H contribution to HSC and IgH class switching defects and malignancies
|
5R01CA161151-03
|
$365,484
|
YAN, CATHERINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The role of Jmjd1c in normal and leukemic hematopoiesis
|
4R00CA168996-03
|
$249,000
|
ZHU, NAN
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Mechanism of Notch-induced leukemogenesis in lymphocytes
|
5R21CA176811-02
|
$178,024
|
WINANDY, SUSAN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Oncogenic Notch Signaling
|
3P01CA119070-09S1
|
$58,609
|
ASTER, JON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Oncogenic Notch Signaling
|
5P01CA119070-09
|
$1,013,309
|
ASTER, JON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-17
|
$2,250,582
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
The Tribbles-COP1 Complex in Leukemia
|
5K08CA166227-03
|
$178,200
|
ULJON, SACHA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
MicroRNA-125b physiologically and pathologically regulates myelopoiesis through I
|
5F30CA183220-02
|
$11,383
|
MEHTA, ARNAV
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Targeting PKM2-InsP3R interaction to treat AML
|
1R21CA186912-01A1
|
$185,247
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-25
|
$4,878,887
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cdk5 signaling in ICN1-induced T Cell Leukemogenesis
|
1R21CA181875-01A1
|
$206,843
|
HUANG, ALEX
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Role of GSK3beta Subcellular Localization in AML Stemness
|
1F30CA186466-01A1
|
$28,116
|
IGNATZ-HOOVER, JAMES
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Next-generation mouse gene-targeting technology to model tumorigenesis
|
5R21CA181859-03
|
$206,843
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S1
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|